ES2172944T3 - Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento. - Google Patents

Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.

Info

Publication number
ES2172944T3
ES2172944T3 ES98959576T ES98959576T ES2172944T3 ES 2172944 T3 ES2172944 T3 ES 2172944T3 ES 98959576 T ES98959576 T ES 98959576T ES 98959576 T ES98959576 T ES 98959576T ES 2172944 T3 ES2172944 T3 ES 2172944T3
Authority
ES
Spain
Prior art keywords
dosage form
coating
osmotic dosage
coat
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98959576T
Other languages
English (en)
Inventor
David E Edgren
Robert R Skluzacek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Application granted granted Critical
Publication of ES2172944T3 publication Critical patent/ES2172944T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Materials For Medical Uses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Forma de dosificación de liberación prolongada (10) que comprende: una composición de fármaco que comprende un fármaco (14) y un excipiente farmacéuticamente aceptable (18); un primer revestimiento (16) que rodea la composición de fármaco, comprendiendo el primer revestimiento (16) etilcelulosa e hidroxialquilcelulosa; un segundo revestimiento (12) que rodea el primer revestimiento (16), comprendiendo el segundo revestimiento (12) una composición permeable al paso de fluido e impermeable al paso de fármaco (14); y una vía de paso de salida (13) en el primer (16) y el segundo (12) revestimientos para la liberación de fármaco (14) a partir de la forma de dosificación (10) durante un periodo de tiempo prolongado.
ES98959576T 1997-12-05 1998-11-23 Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento. Expired - Lifetime ES2172944T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6766997P 1997-12-05 1997-12-05

Publications (1)

Publication Number Publication Date
ES2172944T3 true ES2172944T3 (es) 2002-10-01

Family

ID=22077577

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98959576T Expired - Lifetime ES2172944T3 (es) 1997-12-05 1998-11-23 Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.

Country Status (10)

Country Link
US (1) US6210712B1 (es)
EP (1) EP1035834B1 (es)
AT (1) ATE216220T1 (es)
AU (1) AU1534699A (es)
DE (1) DE69805001T2 (es)
DK (1) DK1035834T3 (es)
ES (1) ES2172944T3 (es)
HK (1) HK1031197A1 (es)
PT (1) PT1035834E (es)
WO (1) WO1999029297A1 (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US8524277B2 (en) 1998-03-06 2013-09-03 Alza Corporation Extended release dosage form
US20050048120A1 (en) * 1998-11-04 2005-03-03 Edgren David Emil Dosage form comprising self-destructive membrane
US20030027789A1 (en) * 2000-01-14 2003-02-06 Ippei Yamaoka Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
BR0212951A (pt) * 2001-09-28 2004-10-26 Mcneil Ppc Inc Formas de dosagens compósitas
CA2363053C (en) * 2001-11-09 2011-01-25 Bernard Charles Sherman Clopidogrel bisulfate tablet formulation
DE60220953T2 (de) * 2002-04-04 2008-02-28 Dr. Reddy's Laboratories Ltd. Pharmazeutische zusammensetzungen enthaltend eine antihistaminische abschwellende arzneistoffkombination und ein verfahren zur herstellung davon
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
EP1534238A1 (en) * 2002-07-29 2005-06-01 ALZA Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050232995A1 (en) * 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20050208132A1 (en) * 2002-07-29 2005-09-22 Gayatri Sathyan Methods and dosage forms for reducing side effects of benzisozazole derivatives
US20070078513A1 (en) * 2002-09-18 2007-04-05 Medtronic Vascular, Inc. Controllable drug releasing gradient coatings for medical devices
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
SI21402A (sl) * 2003-02-12 2004-08-31 LEK farmacevtska dru�ba d.d. Obloženi delci in farmacevtske oblike
FR2857263B1 (fr) * 2003-07-09 2005-09-09 Sanofi Synthelabo Nouvelle composition pharmaceutique solide comprenant de l'amisulpride
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
MXPA06001548A (es) * 2003-08-06 2006-09-04 Johnson & Johnson Suministro uniforme de topiramato durante un periodo prolongado con formulaciones de dispersion.
WO2005020957A2 (en) * 2003-08-22 2005-03-10 Alza Corporation Stepwise delivery of topiramate over prolonged period of time
WO2005020959A2 (en) * 2003-09-02 2005-03-10 Alza Corporation Novel drug compositions and dosage forms of topiramate
US20070065513A1 (en) * 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
AU2004308973A1 (en) * 2003-12-23 2005-07-14 Alza Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
AU2004312084A1 (en) * 2003-12-29 2005-07-21 Alza Corporation, Inc. Novel drug compositions and dosage forms of topiramate
CA2551815A1 (en) * 2003-12-29 2005-07-21 Alza Corporation Novel drug compositions and dosage forms
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US20050287213A1 (en) * 2004-06-28 2005-12-29 Wong Patrick S Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
US20050287212A1 (en) * 2004-06-28 2005-12-29 Liang-Chang Dong Oral delivery system comprising a drug/polymer complex
US8080560B2 (en) * 2004-12-17 2011-12-20 3M Innovative Properties Company Immune response modifier formulations containing oleic acid and methods
WO2006069030A1 (en) * 2004-12-20 2006-06-29 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
JP5002904B2 (ja) * 2005-04-04 2012-08-15 ブラザー工業株式会社 無線タグ通信装置、その通信方法、及びその通信プログラム
EP2026815B1 (en) * 2006-04-26 2011-01-26 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP2041214A4 (en) 2006-07-10 2009-07-08 Medipacs Inc SUPERELASTIC EPOXY HYDROGEL
BRPI0811732A2 (pt) * 2007-06-08 2014-11-18 Boehring Ingelheim Internat Gmbh Formulação de liberação prolongada de nevirapina
US8637080B2 (en) * 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
EP2227635A2 (en) 2007-12-03 2010-09-15 Medipacs, Inc. Fluid metering device
CA2757979A1 (en) * 2009-04-09 2010-10-14 Alkermes Pharma Ireland Limited Controlled-release clozapine compositions
WO2011032011A1 (en) 2009-09-10 2011-03-17 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELS BASED ON POLYSACCHARIDE
US8795727B2 (en) 2009-11-09 2014-08-05 Spotlight Technology Partners Llc Fragmented hydrogels
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20110172639A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Device and method for delivery of microneedle to desired depth within the skin
US20110172609A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Microneedle component assembly for drug delivery device
US20110172637A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Drug delivery device including tissue support structure
US20110172645A1 (en) * 2010-01-08 2011-07-14 Ratio, Inc. Wearable drug delivery device including integrated pumping and activation elements
WO2011086047A1 (en) 2010-01-13 2011-07-21 Azur Pharma Limited Method for titrating clozapine
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
US8668675B2 (en) 2010-11-03 2014-03-11 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
DK2826467T3 (en) 2010-12-22 2017-10-16 Purdue Pharma Lp INCLUDED, MANIPULATION-PROPOSED SLOW-DELIVERY DOSAGE FORMS
CN107412173A (zh) 2010-12-23 2017-12-01 普渡制药公司 抗篡改固体口服剂型
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
AU2013229274A1 (en) * 2012-03-05 2014-09-04 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
EP2847249A4 (en) 2012-03-14 2016-12-28 Medipacs Inc SMART POLYMER MATERIALS WITH EXCESSIVE REACTIVE MOLECULES
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US20140322320A1 (en) * 2013-04-24 2014-10-30 Uday Saxena Novel compositions for emesis control in cancer patients undergoing chemotherapy and methods thereof
CA2914365C (en) 2013-06-05 2022-03-15 Synchroneuron, Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US10973783B2 (en) 2015-12-30 2021-04-13 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
CN115487161B (zh) * 2022-11-18 2023-03-03 山东则正医药技术有限公司 一种氨磺必利片的制备方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2799241A (en) 1949-01-21 1957-07-16 Wisconsin Alumni Res Found Means for applying coatings to tablets or the like
US3173876A (en) 1960-05-27 1965-03-16 John C Zobrist Cleaning methods and compositions
NL271831A (es) 1960-11-29
US3276586A (en) 1963-08-30 1966-10-04 Rosaen Filter Co Indicating means for fluid filters
NL6714885A (es) 1967-11-02 1969-05-06
US3541006A (en) 1968-07-03 1970-11-17 Amicon Corp Ultrafiltration process
US3541005A (en) 1969-02-05 1970-11-17 Amicon Corp Continuous ultrafiltration of macromolecular solutions
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4285987A (en) 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4449983A (en) * 1982-03-22 1984-05-22 Alza Corporation Simultaneous delivery of two drugs from unit delivery device
US4783337A (en) 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4612008A (en) 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4863456A (en) 1986-04-30 1989-09-05 Alza Corporation Dosage form with improved delivery capability
US4743248A (en) * 1986-08-11 1988-05-10 Alza Corporation Dosage form for delivering acid sensitive beneficial agent
US4891223A (en) * 1987-09-03 1990-01-02 Air Products And Chemicals, Inc. Controlled release delivery coating formulation for bioactive substances
US4931285A (en) * 1988-04-28 1990-06-05 Alza Corporation Aqueous based pharmaceutical coating composition for dosage forms
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
ES2054333T3 (es) * 1989-01-30 1994-08-01 Alza Corp Forma de dosificacion para administrar un antagonista del calcio.
DE69107461T2 (de) * 1990-08-07 1995-06-22 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
ATE195252T1 (de) * 1993-04-23 2000-08-15 Novartis Erfind Verwalt Gmbh Wirkstoffabgabevorrichtung mit gesteuerter freigabe
US5674895A (en) * 1995-05-22 1997-10-07 Alza Corporation Dosage form comprising oxybutynin
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Also Published As

Publication number Publication date
WO1999029297A1 (en) 1999-06-17
DE69805001D1 (de) 2002-05-23
EP1035834A1 (en) 2000-09-20
HK1031197A1 (en) 2001-06-08
DE69805001T2 (de) 2002-08-22
DK1035834T3 (da) 2002-07-08
ATE216220T1 (de) 2002-05-15
AU1534699A (en) 1999-06-28
US6210712B1 (en) 2001-04-03
EP1035834B1 (en) 2002-04-17
PT1035834E (pt) 2002-09-30

Similar Documents

Publication Publication Date Title
ES2172944T3 (es) Forma de dosificacion osmotica que comprende un primer y un segundo revestimiento.
GT199800126A (es) Terapia de combinacion.
FI930862A0 (fi) En doseringsform foer tidsvarierande moenster av laekemedeloeverlaotelse
DK196189A (da) Oralt osmotisk dispenseringssystem indeholdende et farmakologisk aktivt stof
BR9604880A (pt) Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
CR6656A (es) Forma de dosificacion de farmacos accionada por un hidrogel
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
MX9706769A (es) Formas de dosificacion farmaceutica que comprenden un inhibidor de la bomba de protones y un agente procinetico.
GEP20033014B (en) Enteric Coated Pharmaceutical Composition and Method of Manufacturing
PT814839E (pt) Formas de dosagem farmaceutica orais que contem um inibidor da bomba de protoes e um faine
DE69434121D1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
ES2167609T3 (es) Formulaciones de quinolona inyectables.
EA199900734A1 (ru) Микрокапсулы, содержащие цис-платину
EE200200565A (et) Vaskulaarse kahjustava toimega kombinatsioonravi
ES2166988T3 (es) Terapia de administracion uniforme de farmacos.
ES2189252T3 (es) Composiciones analgesicas que comprenden un antagonista de la colecistoquinina y un opioide.
ATE234082T1 (de) Adenosin enthaltendes arzneimittel
UY26171A1 (es) Método y formulación farmacéutica para el tratamiento de la discinesia de aparición tardía
ATE461705T1 (de) Verfahren zur erhöhung der magnesiumabsorption und verhinderung von artheriosklerose
ES2187156T3 (es) Terapia antidepresiva.
DE69626544D1 (de) Arzneistoffe
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
AR018321A1 (es) Una forma de dosificacion de liberacion prolongada que comprende oxibutinina y los usos de la oxibutinina y de la forma de dosificacion de liberacionprolongada.
AR013498A1 (es) Uso de ifn-alfa y amantadine para el tratamiento de hepatitis c cronica uso de ifn-alfa

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1035834

Country of ref document: ES